Ultragenyx Pharmaceutical Inc.
RARE
$33.47
$0.100.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.63% | 26.77% | 33.46% | 29.01% | 27.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.63% | 26.77% | 33.46% | 29.01% | 27.44% |
| Cost of Revenue | 6.09% | 6.44% | 6.78% | 8.81% | 96.38% |
| Gross Profit | 8.05% | 10.75% | 12.92% | 6.05% | -314.39% |
| SG&A Expenses | 8.74% | 8.62% | 6.40% | 3.81% | 3.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.97% | 8.26% | 7.94% | 9.24% | 5.53% |
| Operating Income | -1.54% | 7.97% | 11.52% | 5.84% | 9.62% |
| Income Before Tax | -2.79% | 9.62% | 11.07% | 6.72% | 11.62% |
| Income Tax Expenses | 249.14% | 246.12% | 231.47% | 187.51% | -589.67% |
| Earnings from Continuing Operations | -3.73% | 8.92% | 10.40% | 6.17% | 12.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.73% | 8.92% | 10.40% | 6.17% | 12.01% |
| EBIT | -1.54% | 7.97% | 11.52% | 5.84% | 9.62% |
| EBITDA | -1.52% | 8.94% | 13.24% | 7.87% | 12.10% |
| EPS Basic | 8.09% | 24.17% | 26.72% | 23.93% | 28.01% |
| Normalized Basic EPS | 9.54% | 24.92% | 28.41% | 24.47% | 27.39% |
| EPS Diluted | 8.09% | 24.17% | 26.72% | 23.93% | 28.01% |
| Normalized Diluted EPS | 9.54% | 24.92% | 28.41% | 24.47% | 27.39% |
| Average Basic Shares Outstanding | 12.29% | 19.24% | 21.46% | 23.12% | 22.75% |
| Average Diluted Shares Outstanding | 12.29% | 19.24% | 21.46% | 23.12% | 22.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |